SAN DIEGO, Dec. 19, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference:
The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com. A replay will be posted on Illumina's website after the event and will be available for at least 30 days following.
About Illumina
Illumina is improving human health by unlocking the power of the genome. In 2023, we celebrate 25 years of innovation, which has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok and YouTube.
Investors:
Salli Schwartz
+1.858.291.6421
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
David McAlpine
+1.347.327.1336
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$131.68 |
| Daily Change: | -3.32 -2.46 |
| Daily Volume: | 2,964,703 |
| Market Cap: | US$20.980B |
November 19, 2024 November 04, 2024 October 31, 2024 October 09, 2024 August 27, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
